Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06250205 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
A Phase 1 study, sponsored by NewAmsterdam Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06250205 is a Phase 1 study that has completed, run by NewAmsterdam Pharma. The registered enrollment target is 30 participants.
The verdict
NCT06250205, a Phase 1 study, has completed, sponsored by NewAmsterdam Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
Interventions
- DRUG Obicetrapib
- DRUG Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)
- DRUG Drospirenone / Ethinyl Estradiol (COC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-02-05 |
| Est. Completion | 2024-04-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06250205
The ClinicalTrials.gov registry entry for NCT06250205 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NewAmsterdam Pharma, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Obicetrapib is the first listed.
NCT06250205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06250205 about?
NCT06250205 is a clinical study titled "Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib". A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
What is the current status of trial NCT06250205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-02-05. Estimated completion is 2024-04-26.
What interventions are being tested in trial NCT06250205?
The interventions under investigation include: Obicetrapib (DRUG), Obicetrapib + Drospirenone / Ethinyl Estradiol (COC) (DRUG), Drospirenone / Ethinyl Estradiol (COC) (DRUG).
Who is sponsoring clinical trial NCT06250205?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.